Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

NVS

Novartis (NVS)

Novartis AG
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NYSE:NVS
FechaHoraFuenteTítuloSímboloCompañía
30/12/202405:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:NVSNovartis AG
02/12/202406:00PR Newswire (US)PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease ProgramNYSE:NVSNovartis AG
18/11/202407:00PR Newswire (US)Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic CandidateNYSE:NVSNovartis AG
04/11/202405:20IH Market NewsTesla Sales Drop; Intel to Exit Dow Jones After 25 Years; VKTX and ATSG Surge Over 20% Pre-MarketNYSE:NVSNovartis AG
29/10/202404:39IH Market NewsHSBC Reports $8.5 Billion Profit; Boot Barn Announces New CEO and Projections; TMDX Drops 24%, VFC Surges 22%NYSE:NVSNovartis AG
18/10/202405:53PR Newswire (US)Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancerNYSE:NVSNovartis AG
17/10/202415:01Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NYSE:NVSNovartis AG
03/10/202407:45InvestorsHub NewsWireBeyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and MoreNYSE:NVSNovartis AG
16/09/202407:44Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:NVSNovartis AG
16/09/202407:12Edgar (US Regulatory)Form F-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNYSE:NVSNovartis AG
16/09/202405:03IH Market NewsIntel Secures $3.5 Billion Subsidy, Stellantis Backs EU Emissions Targets, BP and Apollo Reach $1 Billion DealNYSE:NVSNovartis AG
10/09/202417:53AllPennyStocks.comJunior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving LivesNYSE:NVSNovartis AG
05/09/202407:00GlobeNewswire Inc.Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14NYSE:NVSNovartis AG
28/08/202411:16Business WireLindy Biosciences stringe un accordo di licenza e collaborazione con Novartis per la somministrazione innovativa di farmaci multitargetNYSE:NVSNovartis AG
28/08/202411:07Business WireLindy Biosciences conclut un accord de licence et de collaboration avec Novartis pour l’innovation en matière d’administration de médicaments à cibles multiplesNYSE:NVSNovartis AG
28/08/202411:06Business WireLindy Biosciences schließt Lizenzierungs- und Kooperationsvereinbarung mit Novartis für Wirkstoffabgabeinnovation für mehrere Zielmoleküle abNYSE:NVSNovartis AG
28/08/202405:58Business WireLindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery InnovationNYSE:NVSNovartis AG
26/08/202407:58IH Market NewsIBM Closes China Research Division, Uber Fined $324M, Starliner to Return Without AstronautsNYSE:NVSNovartis AG
13/08/202415:31Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NYSE:NVSNovartis AG
12/08/202414:30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:NVSNovartis AG
07/08/202418:38PR Newswire (US)Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)NYSE:NVSNovartis AG
06/08/202404:44IH Market NewsGoogle Faces Antitrust Ruling; SunPower Files for Bankruptcy and Business Sale – Latest Business NewsNYSE:NVSNovartis AG
30/07/202406:00GlobeNewswire Inc.Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateNYSE:NVSNovartis AG
18/07/202404:53IH Market NewsTSMC Net Profit Hits $7.6B; Nokia Sees 32% Decline in Operating Profit; Novartis Boosts Outlook After Profit SurgeNYSE:NVSNovartis AG
17/06/202415:30Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NYSE:NVSNovartis AG
25/05/202405:15PR Newswire (US)Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolioNYSE:NVSNovartis AG
25/05/202405:00PR Newswire (US)Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placeboNYSE:NVSNovartis AG
07/05/202406:00GlobeNewswire Inc.Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNYSE:NVSNovartis AG
23/04/202406:25IH Market NewsApple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More NewsNYSE:NVSNovartis AG
15/04/202413:00PR Newswire (US)New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)NYSE:NVSNovartis AG
 Showing the most relevant articles for your search:NYSE:NVS